相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis
J. Ventriglia et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2018)
Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine
Aki Otake et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Prognostic value of postdiagnostic inflammation-based scores in short-term overall survival of advanced pancreatic ductal adenocarcinoma patients
Yuanyuan Xiao et al.
MEDICINE (2017)
Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
Hideki Ueno et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Molecular mechanisms for tumour resistance to chemotherapy
Shu-Ting Pan et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2016)
Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)
David Goldstein et al.
EUROPEAN JOURNAL OF CANCER (2016)
Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer Glasgow Prognostic Score Is the Most Reliable Parameter
Suguru Yamada et al.
MEDICINE (2016)
Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer A Retrospective Cohort Study
Hiroshi Imaoka et al.
PANCREAS (2016)
Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study
Hiroshi Imaoka et al.
PANCREATOLOGY (2016)
Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer
Tatsuya Kurihara et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen
Rujiao Liu et al.
ONCOTARGET (2015)
Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan
Dai Inoue et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2015)
Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients
J. Szkandera et al.
BRITISH JOURNAL OF CANCER (2014)
Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
Takuji Okusaka et al.
CANCER SCIENCE (2014)
Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: An exploratory study of the Gynecologic Oncology Group
Krishnansu S. Tewari et al.
GYNECOLOGIC ONCOLOGY (2014)
Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy
Todd M. Bauer et al.
CANCER (2013)
A retrospective analysis of early CA19-9 change in salvage chemotherapy for refractory pancreatic cancer
Yousuke Nakai et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Association of Rash Severity With Overall Survival Findings from Patients Receiving Erlotinib for Pancreatic Cancer in the Community Setting
Edward J. Stepanski et al.
PANCREAS (2013)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Survival analysis: time-dependent effects and time-varying risk factors
Friedo W. Dekker et al.
KIDNEY INTERNATIONAL (2008)
Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer
Paul Glen et al.
PANCREATOLOGY (2006)
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials
M Di Maio et al.
LANCET ONCOLOGY (2005)
Tumoral drug metabolism: Overview and its implications for cancer therapy
M Michael et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer
DA Cameron et al.
BRITISH JOURNAL OF CANCER (2003)
分享论文
